Marburg virus (MARV) and Sudan virus (SUDV) Vaccines
Closed Solicitation Posted
- Solicitation number
- 75A50125R00006
- Agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- PSC
- 6505 Drugs And Biologicals
- Place of performance
- Washington, District of Columbia, United States
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response, through the Biomedical Advanced Research and Development Authority (BARDA), is seeking to procure monovalent vaccines against Marburg virus (MARV) and Sudan virus (SUDV) for the U.S. civilian population with elevated exposure risk. This solicitation aims to invest Project BioShield funds for advanced development, FDA licensure, procurement, shipping, and vendor-managed inventory storage of these vaccines, which have been identified as high-priority threats by the Department of Homeland Security. Offerors must demonstrate existing or planned domestic manufacturing capabilities, maintain an active FDA investigational new drug application, and provide efficacy data from clinical or non-human primate studies. The government will evaluate proposals based on best overall value, with technical capabilities weighted more heavily than cost. The deadline for questions was July 31, 2025 at 2:00 PM ET, and proposal submissions are due by August 27, 2025 at 2:00 PM ET.
This solicitation does not include any set-aside designations and no incumbent contractors are identified in the documentation. The contract structure is hybrid, combining cost-plus-fixed-fee and firm-fixed-price elements, with a base period of five years and potential option periods extending up to ten years total. The government seeks to procure up to 800,000 total vaccine doses, specifically up to 500,000 licensed vaccine doses and 300,000 pre-licensed doses for each virus strain, delivered in 100,000-dose increments. The vaccines must maintain a minimum four-year stability requirement, with preference given to single-dose vials suitable for healthy adults. Performance will take place in Washington, DC, though the solicitation emphasizes the requirement for domestic manufacturing capabilities within the United States.
Notice text
The 2014 Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Strategy and Implementation Plan identifies Ebola virus and Marburg virus as high-priority threats as determined by the Department of Homeland Security to present a material threat to national security. Strategies to mitigate the threat of Ebola virus and Marburg virus include the development of vaccines suitable for protection against Ebola and Marburg virus disease respectively. BARDA is seeking vaccines that can be safely and effectively used for the U.S. civilian population in individuals with an elevated risk of exposure to Sudan virus (SUDV) and Marburg virus (MARV).
This acquisition will allow BARDA to invest Project BioShield funds for the advanced development, US Food and Drug Administration (FDA) licensure, procurement, shipping, and vendor managed inventory (VMI) storage of MARV and SUDV monovalent vaccines.
Files
| File | Type | Posted |
|---|---|---|
| 75A50125R00006 Amendment 2.pdf | ||
| 75A50125R00006 QA.pdf | ||
| 75A5012R00006 Amendment 001.pdf | ||
| 75A50125R00006.pdf |
Notice history
| Notice | Type | Posted |
|---|---|---|
| This notice | Solicitation | |
| Marburg virus (MARV) and Sudan virus (SUDV) Vaccines | Pre-Solicitation |
Similar open opportunities
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity